Nordic Pharma intros authorized generic of Maxitrol

Nordic Pharma, a subsidiary of Nordic Group B.V., announced a partnership with Harrow, a leading North American eyecare company, to launch an authorized generic of Maxitrol (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension), which treats and relieves bacterial eye infections.

Maxitrol and generic equivalents had annual sales of $20.8 million per IQVIA data, as of January 2025.

[Read more: What do consumers really think about generics?]

"Today marks the culmination of months of work to bring this exciting new authorized generic to the marketplace. This product is a great addition to our generic portfolio, providing patients another affordable prescription option," said Thomas Sammler, vice president of commercial operations.